CD133+ cells isolated from various sources and their role in future clinical perspectives

Expert Opinion on Biological Therapy

Volumn 10, Issue 11, 2010, Pages 1521-1528

  Meregalli, Mirella ^a   Farini, Andrea ^a   Belicchi, Marzia ^a   Torrente, Yvan ^a  

^a Centro Dino Ferrari   (Italy)

Author keywords

CD133+; DMD; Prominin 1; Stem cells

Indexed keywords

CD133 ANTIGEN;

ANTIGEN EXPRESSION; CELL DIFFERENTIATION; CELL ISOLATION; CELL LINEAGE; CELL POPULATION; CELL THERAPY; HUMAN; NONHUMAN; REVIEW; STEM CELL TRANSPLANTATION; TISSUE REGENERATION;

ANIMALS; ANTIGENS, CD; CELL DIFFERENTIATION; CELL LINEAGE; CLINICAL TRIALS AS TOPIC; EPITHELIAL CELLS; GLYCOPROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; ISCHEMIA; MICE; MICE, INBRED NOD; MICE, SCID; MUSCULAR DYSTROPHIES; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASTIC STEM CELLS; ORGAN SPECIFICITY; PEPTIDES; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSPLANTATION, HETEROLOGOUS;

EID: 77958491624     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.528386     Document Type: Review

References (41)

1. Corbeil D, Roper K, Fargeas CA, et al. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001;2:82-91
2. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90:5013-5021
3. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-5012
4. Shmelkov SV, Jun L, St Clair R, et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 2004;103:2055-2061
5. Corbeil D, Roper K, Hellwig A, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000;275:5512-5520
6. Buhring HJ, Seiffert M, Marxer A, et al. AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. Blood 1999;94:832-833
7. Kratz-Albers K, Zuhlsdorp M, Leo R, et al. Expression of a AC133, a novel stem cell marker, on human leukemic blasts lacking CD34-antigen and on a human CD34+ leukemic line:MUTZ-2. Blood 1998;92:4485-4487
8. Torrente Y, Belicchi M, Sampaolesi M, et al. Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest 2004;114:182-195
9. Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000;97:14720-14725
10. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401
11. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110
12. Uchida S, Yokoo S, Yanagi Y, et al. Sphere formation and expression of neural proteins by human corneal stromal cells in vitro. Invest Ophthalmol Vis Sci 2005;46:1620-1625
13. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111-2120
14. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115
15. LaBarge MA, Petersen OW, Bissell MJ. Of microenvironments and mammary stem cells. Stem Cell Rev 2007;3:137-146
16. Sneddon JB, Werb Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell 2007;1:607-611
17. Yen TH, Wright NA. The gastrointestinal tract stem cell niche. Stem Cell Rev 2006;2:203-212
18. Florek M, Haase M, Marzesco AM, et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 2005;319:15-26
19. Ray PN, Belfall B, Duff C, et al. Cloning of the breakpoint of an X;21 translocation associated with Duchenne muscular dystrophy. Nature 1985;318:672-675
20. Matsumura K, Ohlendieck K, Ionasescu VV, et al. The role of the dystrophin-glycoprotein complex in the molecular pathogenesis of muscular dystrophies. Neuromuscul Disord 1993;3:533-535
21. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928
22. Ribatti D. The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 2004;8:294-300
23. Gavina M, Belicchi M, Rossi B, et al. VCAM-1 expression on dystrophic muscle vessels has a critical role in the recruitment of human blood-derived CD133+ stem cells after intra-arterial transplantation. Blood 2006;108:2857-2866
24. Yamamoto K, Kondo T, Suzuki S, et al. Molecular evaluation of endothelial progenitor cells in patients with ischemic limbs: therapeutic effect by stem cell transplantation. Arterioscler Thromb Vasc Biol 2004;24:e192-6
25. Limsuwan A, Pienvichit P, Limpijankit T, et al. Transcoronary bone marrow-derived progenitor cells in a child with myocardial infarction: first pediatric experience. Clin Cardiol 2010;33:E7-12
26. Torrente Y, Belicchi M, Marchesi C, et al. Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplant 2010;16:563-577
27. Bhatia R, Munthe HA, Williams AD, et al. Chronic myelogenous leukemia primitive hematopoietic progenitors demonstrate increased sensitivity to growth factor-induced proliferation and maturation. Exp Hematol 2000;28:1401-1412
28. Lang P, Bader P, Schumm M, et al. Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br J Haematol 2004;124:72-79
29. Stamm C, Westphal B, Kleine HD, et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003;361:45-46
30. Benchaouir R, Meregalli M, Farini A, et al. Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell 2007;1:646-657
31. Flores-Ramirez R, Uribe-Longoria A, Rangel-Fuentes MM, et al. Intracoronary infusion of CD133+ endothelial progenitor cells improves heart function and quality of life in patients with chronic post-infarct heart insufficiency. Cardiovasc Revasc Med;2010:11:72-78
32. Navarro-Sobrino M, Rosell A, Hernandez-Guillamon M, et al. Mobilization, endothelial differentiation and functional capacity of endothelial progenitor cells after ischemic stroke. Microvasc Res 2010 [Epub ahead of print]
33. Smith S, Neaves W, Teitelbaum S. Adult stem cell treatments for diseases? Science 2006;313:439
34. Sampaolesi M, Blot S, D'Antona G, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006;444:574-579
35. Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 2006;12:1397-1402
36. Graf T, Stadtfeld M. Heterogeneity of embryonic and adult stem cells. Cell Stem Cell 2008;3:480-483
37. Negroni E, Riederer I, Chaouch S, et al. In vivo myogenic potential of human CD133+ muscle-derived stem cells: a quantitative study. Mol Ther 2009;17:1771-1778
38. Cossu G, Bianco P. Mesoangioblasts - vascular progenitors for extravascular mesodermal tissues. Curr Opin Genet Dev 2003;13:537-542
39. Grounds MD, McGeachie JK. A model of myogenesis in vivo, derived from detailed autoradiographic studies of regenerating skeletal muscle, challenges the concept of quantal mitosis. Cell Tissue Res 1987;250:563-569
40. Price FD, Kuroda K, Rudnicki MA. Stem cell based therapies to treat muscular dystrophy. Biochim Biophys Acta 2007;1772:272-283
41. Peault B, Rudnicki M, Torrente Y, et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 2007;15:867-877